Medical News
Addiction
Allergies
Alternative Medicine
Asthma
Cancer
Cardiology
Chiropractic
Dental
Dermatology
Diabetes
Emergency
Family Medicine
General
Geriatrics
Hospitals
Infectious Diseases
Internal Medicine
Managed Care / HMO
Medical Products
Mental Health
Neurology
Nursing
Nutrition
OB / GYN
Pediatrics
Pharmaceuticals
Physical Therapy
Plastic Surgery
Psychology
Radiology / Imaging
Research
Sports Medicine
Surgery
Vision

Innovaderm Research Inc. Joins TrialStat's CROFirst Program

Montreal-based Contract Research Organization (CRO) Deploys ClinicalAnalytics 4.0 for its Clinical Trials

Ottowa, ON and Montreal, PQ (PRWEB) June 24, 2008 -- TrialStat Corporation, the industry's first clinical data solutions on demand company, today added Innovaderm Research Inc., a Canadian-based Clinical Research Organization specializing in dermatology, to the growing list of Contract Research Organization's joining TrialStat's CROFirst Program. The CRO channel program provides discounts to promote mutually beneficial joint business development and marketing initiatives between TrialStat and its CRO partners. As a member of CROFirst, Innovaderm can utilize discounts on its CA 4.0 licenses to grow its bottom line and expand its business in partnership with TrialStat in North America.

"We selected TrialStat's CA 4.0 because of its ability to facilitate data collection, data monitoring, and data management in a CRF 21 part 11 environment," said Dr. Robert Bissonnette, President and founder, Innovaderm Research Inc. "CA 4.0 meets our needs with its full or basic service option. CA 4.0's flexibility, functionality and speed will certainly contribute to our long-term business growth."

"We are excited about Innovaderm's participation in our CROFirst program," said Jonathan Barker, President and CEO, TrialStat. "This joint partnership will enable both TrialStat and Innovaderm to more effectively collaborate on activities that promote the benefits of CA 4.0 in the field of dermatological research."

About TrialStat

TrialStat Corporation provides innovative clinical data solutions on demand that optimize the collection and management of research to enable customers to accelerate the commercialization of new life science products. CA 4.0 is a robust and scalable Web-based EDC on demand platform used by leading biopharma organizations. SRS 4.0® automates systematic reviews using real-time collaboration and management tools, while ESRNexus™ (www.esrnexus.com) is the most comprehensive and free Web-based search engine for evidence-based reference literature. More information about TrialStat is available at www.trialstat.com.

About Innovaderm

Innovaderm Research Inc. is a clinical research company that has been active since 1999. Specializing in phase I clinical studies, pilot studies and the proof of concept studies in dermatology, Innovaderm has quickly built a strong reputation for the quality of its clinical research and the care offered to its patients. Innovaderm's complete range of services include study design, protocol development, volunteer recruitment, execution of the clinical trial and writing of the final report. Innovaderm is internationally renowned for its numerous research studies on psoriasis, acne and atopic dermatitis, as well as, for studies involving biological molecules and photodynamic therapies (PDT).

ClinicalAnalytics 4.0 and ESRNexus are registered trademarks of TrialStat Corporation.

SRS 4.0 is a trademark of TrialStat Corporation.

For media inquiries, please contact:

Muay Lim

TrialStat Corporation

613-741-9909 ext 153

###

Simillar Articles

TrialStat CEO to Speak at C-TECH Clinical Technologies Congress
TrialStat Corporation today announced that Jonathan Barker, the company’s President and CEO will speak at the C-TECH Clinical Technologies Congress in Philadelphia, Pennsylvania on Tuesday,...
TrialStat Executive to Speak at Adaptive Clinical Trial Designs Conference
TrialStat Corporation ( www.trialstat.com ), a clinical data solutions on demand company, today announced that Khaled El Emam, the company’s Chief Scientist, will speak at the Adaptive...
SMS-Oncology Joins TrialStat's CROFirst Program
Netherlands-based Contract Research Organization (CRO) deploys ClinicalAnalytics 4.0 for oncology registry study.
TrialStat CEO Jonathan Barker to Speak at Clinical Trials Congress in Las Vegas, Nevada February 7
Jonathan Barker, President and CEO of TrialStat, will speak at the Clinical Trials Congress (CTC) in Las Vegas on February 7 where he will discuss why electronic data capture (EDC) must change to...
TrialStat Executive to Speak at E-Clinical Trials in Canada Conference
TrialStat Corporation, the industry's first clinical data solutions on demand company, today continued to shape discussion around adaptive clinical trials by participating in the E-Clinical...
Home Terms of Use Privacy Policy Contact Us